Huntington’s disease

70
Huntington’s disease Also called Huntington Chorea, affects men and women. 4 to 10 cases in 100,000 people (frequency between 0.004% and 0.01%) . Chorea is defined as brief, irregular, unpredictable, purposeless movements that flow from one body part to another without a rhythmic pattern. HD is a Hyperkinetic Disorder. The symptoms in HD are characterized by Excessive motor activity Involuntary movements (dyskinesias) Decreased muscle tone Behavioral and emotional alteration and cognitive decline, which may precede motor abnormalities. Importance of cognitive and neuropsychological test to identify the pre-symptomatic carriers of the disease.

description

Huntington’s disease. Also called Huntington Chorea, affects men and women. 4 to 10 cases in 100,000 people (frequency between 0.004% and 0.01%) . Chorea is defined as brief, irregular, unpredictable, purposeless movements that flow from one body part to another without a rhythmic pattern . - PowerPoint PPT Presentation

Transcript of Huntington’s disease

Page 1: Huntington’s disease

Huntington’s disease

Also called Huntington Chorea, affects men and women. 4 to 10 cases in 100,000 people (frequency between 0.004% and 0.01%) .

Chorea is defined as brief, irregular, unpredictable, purposeless movements that flow from one body part to another without a rhythmic pattern.

HD is a Hyperkinetic Disorder. The symptoms in HD are characterized by Excessive motor activityInvoluntary movements (dyskinesias)Decreased muscle tone

Behavioral and emotional alteration and cognitive decline, which may precede motor abnormalities. Importance of cognitive and neuropsychological test to identify the pre-symptomatic carriers of the disease.

HD is a dominant autosomal inherited disease characterized by the expansion of a triplet repeat CAG, that encodes for Glutamine, in the N-terminal domain of the protein.

Page 2: Huntington’s disease

George Huntington (1850-1916)

Page 3: Huntington’s disease

Specific localization of Basal Ganglia in a coronal section

Page 4: Huntington’s disease

HD is caused by selective degeneration of the GABAergic neurons in the striatum, in particular in

the caudate

Page 5: Huntington’s disease

HD

Normal

Volumetric analysis in Huntington disease (HD)

Page 6: Huntington’s disease

Age of onset:

HD is thought to be a true dominant disorder, since homozygous carriers of the disease are no more severely affected than heterozygous carriers. In a normal individual, the number of CAG repeats are <36. In HD patients, age of onset when the repeats are 46 ranges between 25 and 52 years old. However, many factors influence the onset of the disease, such as:

Mitochondrial dysfunctionCell death by apoptosisLoss of neurotrophic factorsNeuron excitotoxicity

Length of the CAG repeat and onset of the disease: Inverse correlation, but not when onset is >50 years of age.

Page 7: Huntington’s disease

Deposition of fibrillar proteinacious material in Huntington’s disease

Huntington’s disease: a progressive neurodegenerative disease characterized by CAG repeats causing glutamine expansion motifs (polyQ) in the N-terminal region of the protein huntingtin. Onset of the disease inversely correlates with the number of CAG repeates. Huntingtin can aggregate forming intracellular inclusion bodies that contain also proteasome proteins and ubiquitin. Huntingtin aggregates contain -sheet structures similar to amyloid.

Page 8: Huntington’s disease

In homo sapiens, the gene for huntingtin encodes a large, cytosolic protein, comprised of 3144 aa and with a molecular weight of about 348 kDa.

NH2COOH

aa3144

PolyQ P

In normal individuals, PolyQ<36. In HD patients, PolyQ>36

aa1

Huntingtin

Page 9: Huntington’s disease

NH2

aa3144

PolyQ P

aa1Cleavage by caspase 2, 3, 6calpain

N-terminal fragment

C-terminal fragment

COOH

COOHNH2

Processing of PolyQ, mutant huntingtin

Cdk5, Akt

N-term htt forms aggregates

Page 10: Huntington’s disease

In HD, the aggregates are present in the affected brain regions, although not necessarily in the degenerating neurons

In HD, are the aggregates protecting from neurodegeneration? Are htt oligomers the

most toxic species?

Page 11: Huntington’s disease

Huntington’s disease: loss of function of the wild type huntingtin and gain of

toxic function of the mutant huntingtin

-Heterozygous patients are NOT different in any way from the homozygous patients: in heterozygous patients, the amount of wild-type “good” huntingtin does not make it to “buffer’ the effects of the mutant, PolyQ expanded huntingtin.

-Mutant, PolyQ expanded huntingtin can recruit wild type huntingtin into insoluble aggregates to form the inclusions.

-Neurons with larger inclusions are less compromised than those ones with diffused mutant htt (which might contain oligomers not aggregated into inclusions).

Page 12: Huntington’s disease

Potential mechanism of cell death in Huntington’s disease

Page 13: Huntington’s disease

Which is the physiological role of wild type huntingtin?

-Huntingtin is a molecule required during development, as hungtintin KO mice die at 7.5 postnatal day. Heterozygosity is enough to reach adulthood.

-Huntingtin interacts with several proteins, i.e. cytoskeletal proteins and others that are associated with membrane vesicles, suggesting a role in intracellular trafficking, membrane recycling and retrograde fast axonal transport.

-The presence of Q repeats (CAG) followed by PolyP domain associates with transcriptional regulatory proteins. Inverse correlation between number of CAG repeats and transcriptional activity. After interacting, huntingtin transports transcriptional regulatory proteins in the cytosol and within the nucleus. (BDNF).

Page 14: Huntington’s disease

Physiological roles of wild type huntingtin

Page 15: Huntington’s disease

Physiologic function of wild-type huntingtin:

Cell survival, anti-apoptotic function

Page 16: Huntington’s disease

Immortalized embrional striatal cells

Normal Serum withdrawal

N548Mu

N548WT

Rigamonti et al., 2000

Cell death is prevented by huntingtin wt, but is promoted by huntingtin PolyQ mutant

Page 17: Huntington’s disease

Rigamonti et al., 2000

Temperature-dependent apoptotic DNA fragmentation is sustained by huntingtin PolyQ mutant, but is prevented by huntingtin wt

Page 18: Huntington’s disease

Physiologic function of wild-type huntingtin:

modulating the expression and the transport of BDNF (Brain Derived Growth Factor) to striatal neurons

Page 19: Huntington’s disease

-Peculiarity of HD is that lethality occurs specifically in striatal neurons, although huntingtin is ubiquitously expressed.

-It is known that huntingtin promotes neuronal survival (and is required during development)

-BDNF has certainly a role in maintaining the “health” of striatal neurons. In facts, BDNF:

a)promotes growth and differentiation of striatal neurons

b)protects striatal neurons from excitotoxicity

Page 20: Huntington’s disease

Wild-type huntingtin, but not mutant PolyQ huntingtin, specifically increase the levels of secreted and cellular BDNF

in cell culture

Zuccato et al., 2002

Page 21: Huntington’s disease

BDNF seems likely to be produced in cortex and hippocampus, and to be subsequently transported by afferents to the striatal neurons

What happens in the cortex of HD patients?

Page 22: Huntington’s disease

Levels of BDNF mRNA are reduced in cortex of HD patient

Zuccato et al., 2002

Page 23: Huntington’s disease

Pathogenic mechanisms of mutant PolyQ huntingtin:

Htt processing and formation of aggregates

Page 24: Huntington’s disease

NH2

aa3144

PolyQ P

aa1Cleavage by caspase 2, 3, 6calpain

N-terminal fragment

C-terminal fragment

COOH

COOHNH2

Processing of PolyQ, mutant huntingtin

Cdk5, Akt

N-term fragment forms aggregates

Page 25: Huntington’s disease

N-terminal fragment

NH2

Capabilities to form aggregates

nucleus cytosol

Soluble form

Inhibits Glu Uptake

Glu vesicle

Different translocation of PolyQ, mutant huntingtin N-terminal fragment

activates caspase-1 positive feedback in regulating apoptosis

Page 26: Huntington’s disease

How does the CAG, PolyQ expanded motif cause HD?

-It induces mitochondrial dysfunction, that leads to mitochondrial disruption of Ca++ homeostasis: trigger of cytochrome c and caspase-dependent apoptosis.

-It avoids certain post-translation modifications (like SUMOylation and palmitoylation) to occur on the protein, with consequences on the protein’s functionality.

-The N-terminal fragment translocates to the nucleus where it causes:a) reduction of the synthesis of neurotrophic factors (like BDNF Brain-

Derived Neurotrophic Factor), that are essential for the neuronal growth and life (REST/NRSF).

b) formation of intranuclear aggregates that recruit also transcription factors (CREB binding protein CBP), inducing transcriptional deregulation.

Page 27: Huntington’s disease

Pathogenic mechanisms of mutant PolyQ huntingtin:

Mitochondrial dysfunction

Page 28: Huntington’s disease

Membrane Potential: Difference in the voltage between the two sides of a membrane, caused by an influx and efflux of ions to and from a cell or neuron and an organelle. In the mitochondrion, the membrane potential is caused in particular by exchange of Ca++ ions between the mitochondrion and the cytosol.

Ca++

Ca++

PTPs: Permeability Transition Pores

PTP

Page 29: Huntington’s disease

Panov et al., 2002

Membrane potential and calcium levels are reduced in HD mitochondria

Lymphoblasts

Page 30: Huntington’s disease

Juvenile HD patient: 65 repeatsAdult HD patient: 46 repeats Panov et al., 2002

In HD patients, mitochondrial depolarization occurs at lower Ca++ levels

PTP compromised?

Physiologically, the potential drops when the PTP open

Page 31: Huntington’s disease

The tendency of the PTP to be open directly correlates with the number of PolyQ repeats in huntingtin mutant molecule

Page 32: Huntington’s disease

Huntingtin aggregates are visible on the mitochondrial membrane of PolyQ mutant huntingtin transgenic mice,

but not of wild-type huntingtin transgenic mice

Huntingtin PolyQ mutant transgenic mice

Huntingtin wild-type transgenic micePanov et al., 2002

Page 33: Huntington’s disease

Evidences that Calcium homeostasis is altered

1-in mitochondria of HD patients

2- in mitochondria of transgenic mice over-expressing mutant htt, but not in mice over-expressing wild type htt

3-administration of synthetic PolyQ repeats to human wild-type mitochondria in vitro causes alteration of calcium homeostasis

Altered PTP and mitochondrial calcium homeostasis EARLY EVENT in HD

Page 34: Huntington’s disease

Mutant PolyQ huntingtin disrupts Calcium homeostasis, probably forming aggregates on the mitochondrial membrane that cause abnormal opening of the

Permeability Transition Pores.

Can mutant htt cause mitochondrial dysfunction also using different mechanisms?

Page 35: Huntington’s disease

Serum deprivation increases mitochondrial fragmentation in cells over-expressing mutant htt

HeLa cells

Serum deprivation to induce oxidative stress

Page 36: Huntington’s disease

Mutant htt sensitizes cells to mitochondrial abnormalities following oxidative stress

Page 37: Huntington’s disease

The only over-expression of toxic mutant htt causes mitochondrial fragmentation and dysfunction

Page 38: Huntington’s disease

Mutant htt affecting mitochondrial dynamics?

Page 39: Huntington’s disease

Mitochondrial fusion seems to occur only in cells over-expressing wt htt, but not mutant htt

Page 40: Huntington’s disease

Abolishing fission (Drp1 mutant) or inducing fusion (Mfn2 expression) RESCUES the mitochondrial fragmentation phenotype

Cellular death by apoptosis caused by mutant htt is rescued too

Page 41: Huntington’s disease

Mutant htt PREDISPOSES cells to toxic stimuli leading to increased mitochondrial fission and therefore dysfunction

A role for unbalanced fusion/fission in mitochondrial dysfunction in HD?

Page 42: Huntington’s disease
Page 43: Huntington’s disease

Mutant htt causes mitochondrial fragmentation in fibroblasts of HD patients

Page 44: Huntington’s disease

PolyQ expansion associated with HD impairs mitochondrial movement

Page 45: Huntington’s disease

WT

YAC128

PolyQ expansion associated with HD affects mitochondrial size …

Page 46: Huntington’s disease

…and structure: loss of cristae’s density and presence of constrictions

Side view of outer membrane

“sagittal”

“coronal”

normal

YAC128

Page 47: Huntington’s disease

Human Brains Mitochondrial lysates from mouse brain

Mutant HTT associates with DRP1 in HDColocalization is also found in neurons

Page 48: Huntington’s disease

DRP1 No nucleotides

DRP1+ nucleotides

DRP1+ nucleotides

+httQ ext1-53

Mutant HTT has greater affinity than wt HTT for DRP1: effects on DRP1 GTPase acrivity

DRP1 forms oligomers in presence of GTP (is a GTPase), even thicker in presence of mutant htt.

Page 49: Huntington’s disease

Inactive Drp1 mutant rescues the effects of polyQ htt on mitochondrial fragmentation and cell death (and also transport)

Same effects achieved also by over-expression on Mfn2

Page 50: Huntington’s disease

Re-established mitochondrial fission and fusion balance improves the toxic effects of polyQ htt on mitochondrial motility, fragmentation and on cell death.

Page 51: Huntington’s disease

PolyQ htt binds to Drp1 and disrupts the equilibrium between fission and fusion: a model for htt toxicity in HD

Page 52: Huntington’s disease

Autophagy in HD:Loss of physiologic function of mutant htt

Page 53: Huntington’s disease

LC3II accumulates in HD: autophagy is induced or is defective?

Page 54: Huntington’s disease

Rescuing autophagy with Rapamycin reverts the eye degenerating phenotype in htt mutant flies

Autophagy as a protective mechanism against HD

Page 55: Huntington’s disease

Autophagic activity is reduced in HD cellsProtein degradation in MEF from wt or mutant htt knock in mice

Page 56: Huntington’s disease

What happens at an autophagosome level?

Page 57: Huntington’s disease

Autophagosomes are correctly formed and are abundant in HD cells

H O W E V E R . . . . . .

Page 58: Huntington’s disease

The cytosolic content in HD autophagosomes seems to differ from normal autophagosomes

Page 59: Huntington’s disease

Inefficient engulfment of cytosolic components by autophagosomes in HD cells

Page 60: Huntington’s disease

Macroautophagy is inefficient in HD cells

Does the cell “give up” on autophagy in HD, or does it try to compensate with other mechanisms?

Page 61: Huntington’s disease
Page 62: Huntington’s disease

Protein degradation that does not depend on macroautophagy is increased in HD cells

Page 63: Huntington’s disease

CMA reporter is more evident in HD cells in typical autophagic punctae…

Page 64: Huntington’s disease

…and co-localizes with LC3, an autophagy related protein

Page 65: Huntington’s disease

In HD cells, lysosomal CMA receptor LAMP-2 is upregulated and functional…

Page 66: Huntington’s disease

HD mouse brain

Up-regulation of CMA receptor Lamp-2 also in vivo, in the brain of HD mice

Page 67: Huntington’s disease

…and in dopaminergic neurons too

Page 68: Huntington’s disease

LAMP-2 transcription and stability is increased in HD cells

Page 69: Huntington’s disease

Therapy for HD-Possible presymptomatic treatment, after genetic test.-Symptomatic treatments aimed at treating:

DepressionPsychosis

ChoreaTetrabenazine, depletes DA from central neurons.

-Mutant Htt siRNA

-Caspase inhibitors (risks of higher susceptibility to develop cancer after a long-term treatment). Minocycline (antibiotic already in use in humans) used now in clinical trails for HD. In HD prevents apoptosis by inhibiting caspases and mitochondrial permeability. Possible other unknown mechanisms of action.

-Enhancing the clearance of mutant Htt, for example by autophagy.

-NMDA receptors antagonists to block glutamate-induced excitotoxicity.

-To induce wt Htt physiological function

Page 70: Huntington’s disease

Potential therapeutic strategies in HD